Literature DB >> 27895799

Routine blood examinations combined with morphological analysis for the diagnosis of myelodysplastic/myeloproliferative neoplasms.

Huanling Wu1, Hui Sun1, Zhifen Zhang1, Xiangli Li2, Yuantang Li1, Li Li1, Rui Xu1, Zie Wang1, Wenjun Tian1.   

Abstract

In 2008, the World Health Organization (WHO) introduced a new hematological neoplasm category; myelodysplastic/myeloproliferative neoplasms (MDS/MPN), which included four main subcategories. This disease is often misdiagnosed, which delays effective therapy. The present study evaluated the role of routine blood examinations and morphological analysis of peripheral blood cells in the reliable diagnosis of MDS/MPN. In total, 236 adult MDS/MPN patients were analyzed. The analysis included 10 routine blood parameters measured using a Sysmex XE-2100™, 3 differential percentage parameters and 7 morphological features of peripheral blood cells which were analyzed by optical microscopy, and 3 differential absolute count numbers obtained based on the corresponding differential percentages and absolute count of blood cells. The parameters were compared among the subcategories and a value of P<0.05 was considered to indicate a statistically significant difference. The median white blood cell and hemoglobin counts of the patients were 18.0×109/l and 88 g/l, respectively. The proportion of monocytes increased to 8% (1.82×109/l), the proportion of blast cells increased to 1% (0.5×109/l) and that of neutrophil precursors increased to 10% (1.98×109/l). A total of 87% of all patients presented with hypogranulation and 71% presented with abnormal condensed nuclear chromatin in granulocytes. Atypical monocytes were observed in 73% of all patients and Pseudo-Pelger cells were observed in 60%. Significant differences were detected among the subcategories. The present study demonstrated that combining blood routine parameters and the morphological analysis of peripheral blood cells have an essential role in the reliable diagnosis of MDS/MPN based on WHO categories.

Entities:  

Keywords:  blood routine examination; diagnosis; morphological analysis; myelodysplastic/myeloproliferative neoplasms

Year:  2016        PMID: 27895799      PMCID: PMC5104262          DOI: 10.3892/ol.2016.5165

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

1.  Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia.

Authors:  M Koldehoff; N K Steckel; Y Hegerfeldt; M Ditschkowski; D W Beelen; A H Elmaagacli
Journal:  Int J Lab Hematol       Date:  2011-06-27       Impact factor: 2.877

Review 2.  Myelodysplastic/myeloproliferative neoplasms.

Authors:  Elizabeth Hyjek; James W Vardiman
Journal:  Semin Diagn Pathol       Date:  2011-11       Impact factor: 3.464

Review 3.  Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Authors:  Christopher B Benton; Aziz Nazha; Naveen Pemmaraju; Guillermo Garcia-Manero
Journal:  Crit Rev Oncol Hematol       Date:  2015-03-14       Impact factor: 6.312

Review 4.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

Review 5.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

6.  Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.

Authors:  Wolfgang Kern; Ulrike Bacher; Susanne Schnittger; Tamara Alpermann; Claudia Haferlach; Torsten Haferlach
Journal:  Cytometry B Clin Cytom       Date:  2013-01-02       Impact factor: 3.058

7.  Morphological evaluation of monocytes and their precursors.

Authors:  Jean E Goasguen; John M Bennett; Barbara J Bain; Teresa Vallespi; Richard Brunning; Ghulam J Mufti
Journal:  Haematologica       Date:  2009-06-16       Impact factor: 9.941

8.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Authors:  Sa A Wang; Robert P Hasserjian; Patricia S Fox; Heesun J Rogers; Julia T Geyer; Devon Chabot-Richards; Elizabeth Weinzierl; Joseph Hatem; Jesse Jaso; Rashmi Kanagal-Shamanna; Francesco C Stingo; Keyur P Patel; Meenakshi Mehrotra; Carlos Bueso-Ramos; Ken H Young; Courtney D Dinardo; Srdan Verstovsek; Ramon V Tiu; Adam Bagg; Eric D Hsi; Daniel A Arber; Kathryn Foucar; Raja Luthra; Attilio Orazi
Journal:  Blood       Date:  2014-03-13       Impact factor: 22.113

Review 9.  Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.

Authors:  Ramon V Tiu; Mikkael A Sekeres
Journal:  Curr Opin Hematol       Date:  2014-03       Impact factor: 3.284

10.  Characteristics of the four subtypes of myelodysplastic/myeloproliferative neoplasms.

Authors:  Huanling Wu; Shuquan Bian; Jingxue Chu; Xiaoyan Zhong; Hui Sun; Bingchang Zhang; Zhiming Lu
Journal:  Exp Ther Med       Date:  2013-02-26       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.